{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T22:40:09Z","timestamp":1752532809621,"version":"3.41.2"},"reference-count":7,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,14]]},"DOI":"10.7759\/cureus.87927","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T22:01:40Z","timestamp":1752530500000},"source":"Crossref","is-referenced-by-count":0,"title":["Sustained Efficacy and Safety of Tildrakizumab in Psoriasis Vulgaris Despite Multiple Prolonged Treatment Interruptions: A Case Report"],"prefix":"10.7759","author":[{"given":"Kazuki","family":"Yatsuzuka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Muto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Shiraishi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhiro","family":"Fujisawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18484","article-title":"Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies","volume":"182","author":"Kimball AB","year":"2020","unstructured":"Kimball AB, Papp KA, Reich K, et al.. Efficacy and safety of tildrakizumab for plaque psoriasis with continuous dosing, treatment interruption, dose adjustments and switching from etanercept: results from phase III studies. Br J Dermatol. 2020, 182:1359-68. 10.1111\/bjd.18484","journal-title":"Br J Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00725","article-title":"Immunogenicity of bioproducts: cellular models to evaluate the impact of therapeutic antibody aggregates","volume":"11","author":"Nabhan M","year":"2020","unstructured":"Nabhan M, Pallardy M, Turbica I. Immunogenicity of bioproducts: cellular models to evaluate the impact of therapeutic antibody aggregates. Front Immunol. 2020, 11:725. 10.3389\/fimmu.2020.00725","journal-title":"Front Immunol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103530","article-title":"Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: an analysis of current evidence","volume":"23","author":"Sun X","year":"2024","unstructured":"Sun X, Cui Z, Wang Q, et al.. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: an analysis of current evidence. Autoimmun Rev. 2024, 23:103530. 10.1016\/j.autrev.2024.103530","journal-title":"Autoimmun Rev"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kex434","article-title":"Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far","volume":"57","author":"Jani M","year":"2018","unstructured":"Jani M, Dixon WG, Chinoy H. Drug safety and immunogenicity of tumour necrosis factor inhibitors: the story so far. Rheumatology (Oxford). 2018, 57:1896-907. 10.1093\/rheumatology\/kex434","journal-title":"Rheumatology (Oxford)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16803","article-title":"Intermittent use of biologic agents for the treatment of psoriasis in adults","volume":"35","author":"Al-Hammadi A","year":"2021","unstructured":"Al-Hammadi A, Ruszczak Z, Magari\u00f1os G, Chu CY, El Dershaby Y, Tarcha N. Intermittent use of biologic agents for the treatment of psoriasis in adults. J Eur Acad Dermatol Venereol. 2021, 35:360-7. 10.1111\/jdv.16803","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16980","article-title":"Immunogenicity of biologic therapies in psoriasis: myths, facts and a suggested approach","volume":"35","author":"Tsakok T","year":"2021","unstructured":"Tsakok T, Rispens T, Spuls P, Nast A, Smith C, Reich K. Immunogenicity of biologic therapies in psoriasis: myths, facts and a suggested approach. J Eur Acad Dermatol Venereol. 2021, 35:329-37. 10.1111\/jdv.16980","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.5021\/ad.2018.30.2.179","article-title":"Economic burden can be the major determining factor resulting in short-term intermittent and repetitive ustekinumab treatment for moderate-to-severe psoriasis","volume":"30","author":"Choi CW","year":"2018","unstructured":"Choi CW, Choi JY, Kim BR, Youn SW. Economic burden can be the major determining factor resulting in short-term intermittent and repetitive ustekinumab treatment for moderate-to-severe psoriasis. Ann Dermatol. 2018, 30:179-85. 10.5021\/ad.2018.30.2.179","journal-title":"Ann Dermatol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/389512-sustained-efficacy-and-safety-of-tildrakizumab-in-psoriasis-vulgaris-despite-multiple-prolonged-treatment-interruptions-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T22:01:41Z","timestamp":1752530501000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/389512-sustained-efficacy-and-safety-of-tildrakizumab-in-psoriasis-vulgaris-despite-multiple-prolonged-treatment-interruptions-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":7,"URL":"https:\/\/doi.org\/10.7759\/cureus.87927","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,14]]}}}